Open Access

Cisplatin plus vinorelbine as induction treatment in stage IIIA non‑small cell lung cancer

  • Authors:
    • Magda Palka
    • Antonio Sanchez
    • Mar Córdoba
    • Gema Díaz Nuevo
    • Andrés Varela De Ugarte
    • Blanca Cantos
    • Miriam Méndez
    • Virginia Calvo
    • Constanza Maximiano
    • Mariano Provencio
  • View Affiliations

  • Published online on: January 18, 2017     https://doi.org/10.3892/ol.2017.5620
  • Pages: 1647-1654
  • Copyright: © Palka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Survival rates in patients with stage IIIA non-small cell lung cancer (NSCLC) remain low despite curative treatment. This is due to tumor recurrence at distant sites. The aim of neoadjuvant chemotherapy (NA‑CT) is to eradicate occult micrometastatic disease and improve survival in patients that are not candidates for surgery following induction therapy. A total of 21 patients with ipsilateral mediastinal node involvement (N2) with potentially resectable disease, who had been diagnosed with stage IIIA (T1‑3 N1‑2 and T4N0) NSCLC and who had received cisplatin and vinorelbine as induction treatment were included in this retrospective study. Patients who responded to the treatment underwent surgery, and those who were unresponsive received radical radiotherapy. Follow‑up was conducted between March 2008 and April 2014. The median age of patients was 61 years, and all patients exhibited a good Eastern Cooperative Oncology Group performance status. The majority of patients were histologically diagnosed with adenocarcinoma (48%) or squamous cell carcinoma (38%), which was a poor prognostic factor for overall survival (OS). A total of 7 patients underwent surgery (of which 6 were down‑staged), with a 3‑year survival rate of 42.8%. The most significant factor associated with response to induction treatment was multistation nodal involvement. The complete resection rate for surgical patients was 85.7%. Unresectable patients had a 3‑year survival rate of 25.8%. OS time for the whole cohort was 28.5 months, and the 3‑ and 5‑year OS rates were 28.5% and 4.7%, respectively. CT‑induced toxicity did not affect any treatment regime or surgical procedures. In conclusion, the use of cisplatin plus vinorelbine is feasible in a neoadjuvant setting, with good response rates and acceptable toxicity. Multistation N2 involvement is the main prognostic factor for a poor response to induction treatment.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Palka M, Sanchez A, Córdoba M, Díaz Nuevo G, Varela De Ugarte A, Cantos B, Méndez M, Calvo V, Maximiano C, Provencio M, Provencio M, et al: Cisplatin plus vinorelbine as induction treatment in stage IIIA non‑small cell lung cancer. Oncol Lett 13: 1647-1654, 2017
APA
Palka, M., Sanchez, A., Córdoba, M., Díaz Nuevo, G., Varela De Ugarte, A., Cantos, B. ... Provencio, M. (2017). Cisplatin plus vinorelbine as induction treatment in stage IIIA non‑small cell lung cancer. Oncology Letters, 13, 1647-1654. https://doi.org/10.3892/ol.2017.5620
MLA
Palka, M., Sanchez, A., Córdoba, M., Díaz Nuevo, G., Varela De Ugarte, A., Cantos, B., Méndez, M., Calvo, V., Maximiano, C., Provencio, M."Cisplatin plus vinorelbine as induction treatment in stage IIIA non‑small cell lung cancer". Oncology Letters 13.3 (2017): 1647-1654.
Chicago
Palka, M., Sanchez, A., Córdoba, M., Díaz Nuevo, G., Varela De Ugarte, A., Cantos, B., Méndez, M., Calvo, V., Maximiano, C., Provencio, M."Cisplatin plus vinorelbine as induction treatment in stage IIIA non‑small cell lung cancer". Oncology Letters 13, no. 3 (2017): 1647-1654. https://doi.org/10.3892/ol.2017.5620